Dedicated Import of Medical Devices in Brazil

Integrated solutions for regulatory and logistics access Importing medical devices efficiently requires a dedicated process ranging from market research to customs clearance. QR Group performs a full dedicated import service, coordinating each step with technical and regulatory precision. Starting with the correct classification of the product, through the appointment of a local representative or qualified […]
BRH: Registration Representation for Foreign Manufacturers

Registration Holder Service: your link with ANVISA Foreign medical device manufacturers can only distribute in Brazil if they appoint a Brazilian Registration Holder (BRH). This official representative acts as a bridge between your company and ANVISA, assuming legal responsibilities, keeping the registration active, and ensuring the GMP certification necessary for regulatory compliance. Why a standalone […]
Medical Device Registration: Agile Compliance with ANVISA

Understand the Medical Device Registration Process at ANVISA Ensuring access to the Brazilian market requires a detailed regulatory process, especially in the registration of medical devices with ANVISA. QR Group’s registration service was developed to facilitate this journey, ensuring compliance, agility, and strategy for companies that want to operate safely in the health sector. Complying […]
QR Group Explains How to Sell Class III and IV Medical Devices in Brazil: Certification and Compliance Requirements

Learn how to obtain the GMP certification required to register Class III and IV medical devices with ANVISA with the help of QR Group. To market Class III, Class IV or IVD medical devices in Brazil, it is essential that foreign manufacturers obtain Good Manufacturing Practices (GMP) certification from ANVISA. This process is crucial to […]
QR Group: How to Register Health Products with ANVISA and Ensure Compliance

Learn how QR Group can assist in the registration of health products with ANVISA and in the regulatory process to ensure entry into the Brazilian market. For a health product to be legally marketed in Brazil, it is essential that it goes through the registration process with ANVISA. This process involves a series of steps […]
Update of Brazilian Common Names: What Has Changed and How It Impacts the Pharmaceutical Sector

Understand ANVISA’s New Update and Its Impact on the Registration of Pharmaceutical Ingredients ANVISA published, in the Official Gazette of the Union, Normative Instruction 343/2025, which brings important changes to the list of Brazilian Common Denominations (DCBs). Eight new denominations were included, and one was changed, reinforcing the need for continuous updating of companies in […]
QR Group Analyzes the Debate on Regulation of Food Ingredients by Anvisa

Main Conclusions of Anvisa’s Sector Dialogue On 03/14, Anvisa held a virtual sector dialogue to discuss the regulation of food ingredient specifications, as defined by Project 3.8.1 of the 2024/2025 Regulatory Agenda. QR Group, a specialist in sanitary regulation, closely followed the discussions and highlights the main points addressed and their impacts on companies in […]
ANVISA Selects Priority Foreign Authorities to Strengthen Regulatory Confidence

Impact for Medical Device and Drug Manufacturers The National Health Surveillance Agency (ANVISA) approved, at a meeting of the Committee for Strategic Management, Risks and Institutional Innovation (CGE), the list of priority Foreign Regulatory Authorities. This decision aims to consolidate regulatory trust (“reliance”), accelerating registration and inspection processes of medicines and medical devices in Brazil. […]
Anvisa Gets a Grade 10 Performance in Good Regulatory Practices: Understand the Impact and How QR Group Can Help in the Process

CGU audit recognizes Anvisa’s excellence in good regulatory practices; learn how this reflects on healthcare product regulation and how QR Group supports manufacturers. The Office of the Comptroller General of the Union (CGU) recently evaluated Anvisa, along with other regulatory agencies, regarding the adoption of good regulatory practices. Anvisa stood out for meeting all the […]
Regularization of Cannabis-Based Products for Veterinary Use

Understand how the new measure impacts the regulation of veterinary products and how QR Group can help companies in the process. On October 30, ANVISA’s Collegiate Board approved a measure that allows the regularization of cannabis-based products for veterinary use by the Ministry of Agriculture and Livestock (MAPA). The decision amends Ordinance SVS/MS 344/1998, allowing […]